Mutations of katG and inhA in MDR M. tuberculosis

Tuberculosis and Respiratory Diseases

Volumn 63, Issue 2, 2007, Pages 128-138

  Hai, Hua Lin ^a   Kim, Hee Youn ^a   Yun, Yeo Jun ^a   Chan, Geun Park ^a   Kim, Bum Joon ^a,b   Park, Young Gil ^c   Kook, Yoon Hoh ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Korean Institute of Tuberculosis   (South Korea)

Author keywords

INH; inhA; katG; M. tuberculosis; MDR TB; Mutation

Indexed keywords

BACTERIAL DNA; KATG PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CODON; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; INHA GENE; KATG GENE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGION; SEQUENCE ANALYSIS;

EID: 36549032910     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2007.63.2.128     Document Type: Article

References (41)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86.
2. Bai GH. Anti-tuberculosis drug resistance in Korea. Communicable Diseases Monthly Report 2005;16:101-7.
3. Crofton J, Chaulet P, Maher D, Grosset J, Harris W, Norman H, et al. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization; 1997.
4. World Health Organization Anti-tuberculosis drug resistance in the world the WHO/IUATLD global project on antituberculosis drug resistance surveillance 1994-1997. Geneva: World Health Organization;1997.
5. Kim SY, Lee JY, Ryu SR, Kim SJ, Bai GH. Rapid diagnosis of isoniazid resistance by detection of mutations in katG and inhA of Mycobacterium tuberculosis in Korea J Bacteriol Virol 1997;32:569-76.
6. Park YK, Shim MS, Cho SH, Bai GH, Kim SJ. The relationship between isoniazid resistance and 463 codon mutation of katG gene in Mycobacterium tuberculosis. Tuberc Respir Dis 1996;43:8-13.
7. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202.
8. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003;47:3799-805.
9. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase- peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
10. Heym B, Zhang Y, Poulet S, Young D, Cole ST. Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 1993;175:4255-9.
11. O'Brien KL, Dietz HC, Romagnoli M, Fiden J. Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates. Mol Cell Probes 1996; 10:1-6.
12. Lee AS, Tang LL, Lim IH, Ling ML, Tay L, Wong SY. Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore. J Infect Dis 1997;176:1125-7.
13. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
14. Larsen MH, Vilcheze C, Kremer L, Besra GS, Parsons L, Salfinger M, et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002;46:453-66.
15. Basso LA, Zheng R, Musser JM, Jacobs WR, Blanchard JS. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid resistant clinical isolates. J Infect Dis 1998;178: 769-75.
16. Kapur V, Li LL, Hamrick MR, Plikaytis BB, Shinnick TM, Telenti A, et al. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
17. Ristow M, Möhlig M, Rifai M, Schatz H, Feldmann K, Pfeiffer A. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 1995;346:502-3.
18. Lee H, Cho SN, Bang HE, Lee JH, Bai GH, Kim SJ, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea. Int J Lung Dis 2000;4:441-7.
19. Morris S, Bai GH, Suffys P, Portillo-Gomez L, Fairchok M, Rouse D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J Infect Dis 1995; 171:954-60.
20. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and isoniazid-susoeptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
21. Rouse DA, Li Z, Bai GH, Morris SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2472-7.
22. Gonzalez N, Torres MJ, Aznar J, Palomares JC. Molecular analysis of rifampin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in Seville, Spain. Tuber Lung Dis 1999;79:187-90.
23. Heym B, Honore N, Truffot-Pemot C, Banerjee A, Schurra C, Jacobs WR, et al. Implications of multi-drug resistance for the future short-course chemotherapy of tuberculosis: a molecular study. Lancet 1994;344:293-8.
24. Rinder H, Thomschke A, Rüsch-Gerdes S, Bretzel G, Feldmann K, Rifai M, et al. Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 1998;17:508-11.
25. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2003; 41:4471-4.
26. Lee AS, Lim IH, Tang LL, Telenti A, Wong SY. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 1999;43: 2087-9.
27. Lee AS, Teo AS, Wong SY. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2001;45:2157-9.
28. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, et al. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase gene (rpoB). J Clin Microbiol 1999;37:1714-20.
29. Shim TS, Yoo CG, Han SK, Shim YS, Kim YW. Isoniazid resistance and the point mutation of codon 463 of katG gene of Mycobacterium tuberculosis. J Korean Med Sci 1997;12:92-8.
30. Marttila HJ, Soini H, Huovinen P, Viljanen MK. katG mutations in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from Finnish patients. Antimicrob Agents Chemother 1996;40:2187-9.
31. Altamirano M, Marostenmaki J, Wong A, FitzGerald M, Black WA, Smith JA. Mutations in the catalase-mperoxidase gene from isoniazid resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994;169:1162-5.
32. Cockerill FR 3rd, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 1995;171:240-5.
33. Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995;15:235-45.
34. Rouse DA, Morris SL. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis. Infect Immun 1995;63: 1427-33.
35. Bakonyte D, Baranauskaite A, Cicenaite J, Sosnovskaja A, Stakenas P. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob Agents Chemother 2003;47:2009-11.
36. Torres MJ, Criado A, Gónzalez N, Palomares JC, Aznar J. Rifampin and isoniazid resistance associated mutations in Mycobacterium tuberculosis clinical isolates in Seville, Spain Int J Tuberc Lung Dis 2002;6:160-3.
37. Pretorius GS, van Helden PD, Sirgel F, Eisenach KD, Victor TC. Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother 1995;39:2276-81.
38. Bobadilla-del-Valle M, Ponce-de-Leon A, Arenas-Huertero C, Vargas-Alarcon G, Kato-Maeda M, Small PM, et al. rpoB gene mutations in rifampin-resistant Mycobacterium tuberculosis identified by polymerase chain reaction single-stranded conformational polymorphism Emerg Infect Dis 2001;7:1010-3.
39. Moghazeh SL, Pan X, Arain T, Stover CK, Musser JM, Kreiswirth BN. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40:2655-7.
40. Williams DL, Spring L Collins L, Miller LP, Heifets LB, Gangadharam PR, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1853-7.
41. Bodmer T, Zürcher G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995;35:345-8.